The Global. If the price of biosimilars were 40 percent cheaper than their reference biologicals, they would provide a total saving of 98.000 million euros until 2020, according to the latest report on this market published by the consultancy IMS Health, which takes into account the US market and the five most important European markets -Germany, France, Italy, the United Kingdom and Spain-.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
